Physiologically Based Pharmacokinetic Modeling in Patients With Hepatic Impairment: Are Changes in Bosutinib Exposure Profiles Driven by Altered Absorption or Distribution?

Key Points

• To investigate how changes in bosutinib exposure profiles are influenced by absorption and distribution in patients with hepatic impairment.
• Used physiologically based pharmacokinetic modeling techniques.
• Analyzed the impact of hepatic impairment on bosutinib's oral exposure profiles.
• Considered bosutinib's metabolism and transport via P‐glycoprotein and CYP3A4.
• Identified atypical changes in bosutinib exposure in hepatic impairment patients.
• Proposed that altered absorption or distribution may drive these changes.
• Emphasized the role of pharmacokinetics in the management of patients with liver issues.